Hansoh Pharma (03692) has announced its interim results for the six months ended June 30, 2026, revealing a notable increase in profitability. The group reported revenue of RMB 8.304 billion, marking an 11.71% year-on-year growth. Profit attributable to shareholders of the parent company reached RMB 4.258 billion, reflecting a robust 35.82% increase compared to the same period last year.

Earnings per share stood at RMB 0.7, with the company declaring an interim dividend of HK 28.5 cents per share. According to the company's announcement, the rise in profit and basic earnings per share during the reporting period was primarily driven by higher revenue from innovative drugs, alongside an increase in other income.

During the six-month period, the group had over 70 ongoing clinical trials for innovative drugs, encompassing more than 40 candidate drug candidates in its pipeline.